Biotech | March 18, 2022
Sanofi moves forward with EUROAPI listing on Euronext Paris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
He has over 25 years of rich experience in marketing and business in various sectors
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Subscribe To Our Newsletter & Stay Updated
